

MyHOPE™ for Multiple Myeloma Pilot Study



A Multi-Center, Randomized, Pilot Trial to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) for Multiple Myeloma (MM) Digital Care Network in Patients With MM^{1,2}

The MyHOPE™ for MM Platform is a validated investigational device designed to provide patients with a comprehensive set of tools and resources to support their overall experience with MM.

The platform consists of a smartphone app, on which patients collect biometrics and self-reported data, and a desktop HCP portal for HCPs to view patient-entered data.

The MyHOPE™ for MM pilot trial is a prospective study evaluating the impact of a digital health platform for patients with hematological malignancies.

CURRENTLY ENROLLING IN THE US


NDS-MM-004 NCT04730505

PRIMARY ENDPOINTS

- Monthly eligibility and recruitment rates per month of patients with MM
- User average weekly log-in rates over the duration of follow-up from patients with MM and HCPs
- Duration of follow-up
- Patient-reported outcome completion rates
- Frequency of user access by feature and by month, relative to the enrollment date of each participant
- Percentage of patients for whom the HCPs complete the 6-month assessments
- Patient empowerment and self-efficacy measured by CASE-cancer

SECONDARY ENDPOINTS

- Proportion of respondents scoring 4 or 5 on the Patient Platform Usability Survey or HCP Platform Survey
- Quality of life measured by FACT-MM total score



Stratified by disease status (NDMM TNE, NDMM TE, NDMM ASCT, and RRMM)



CONTACT: ClinicalTrialDisclosure@bms.com

The MyHOPE™ Platform has not been approved by the United States Food and Drug Administration (FDA), nor any other regulatory authority. Its use in this study is investigational.

ASCT, autologous stem cell transplant; CASE-cancer, Communication and Attitudinal Self-Efficacy scale for cancer; FACT-MM, Functional Assessment of Cancer Therapy-Multiple Myeloma; HCP, healthcare professional; HRQoL, health-related quality of life; MM, multiple myeloma; MyHOPE, My Hematology Oncology Patient Experience; NDMM, newly diagnosed multiple myeloma; RRMM, relapsed and/or refractory multiple myeloma; TE, transplant eligible; TNE, transplant ineligible.

1. ClinicalTrials.gov. NCT04730505. Accessed April 7, 2021. 2. Raju N et al. Pilot trial of the My Hematology Oncology Patient Experience (MyHOPE™) for multiple myeloma (MM)—digital solution for patients with MM. Poster presentation at ASH 2020. Abstract 1603.

MyHOPE is a trademark of Celgene Corporation, a Bristol-Myers Squibb company.

©2021 Bristol-Myers Squibb Company. All rights reserved. VV-MED-01822 NP-WWM-NA-0119 05/21